SAUNDERS, AMSTERDAM, NL, vol.11, no.6, 25 October 2007 (2007-10-25), pages 485-496, XP022341295, ISSN: 1087-0792, DOI: 10.1016/J.SMRV.2007.08.001, WALDEMAR OCKERT: "A new dawn in the sleep disorders pipeline?", NATURE REVIEWS DRUG DISCOVERY, vol. 11, no.8, 20 July 2012 (2012-07-20), pages 595-596, XP055057972, ISSN: 1474-1776, DOI: 10.1038/nrd3789, RAJARATNAM S M ET AL: "Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials", THE LANCET, LANCET LIMITED. LONDON, GB, vol.373, no.9662, 7 February 2009 (2009-02-07), pages 482-491, XP025913508, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(08)61812-7 [retrieved on 2009-02-05], HARDELAND RUEDIGER: "Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders", CURRENT OPINION IN INVESTIGATIONAL DRUGS, THOMSON REUTERS (SCIENTIFIC) LTD, LONDON, UK, vol.10, no.7, 1 July 2009 (2009-07-01), pages 691-701, XP008161049, ISSN: 2040-3429, HARDELAND R: "New approaches in the management of insomnia: Weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists", NEUROPSYCHIATRIC DISEASE AND TREATMENT, DOVE MEDICAL PRESS (NZ) LTD, NZ, vol.5, no.1, 1 January 2009 (2009-01-01) , pages 341-354, XP009137641, ISSN: 1176-6328 [retrieved on 2009-06-10], UCHIYAMA M ET AL: "Non-24-Hour Sleep-Wake Syndrome in Sighted and Blind Patients", SLEEP MEDICINE CLINICS, W.B. SAUNDERS CO, US, vol.4, no.2, 1 June 2009 (2009-06-01), pages 195-211, XP008161124, ISSN: 1556-407X, DOI: 10.1016/J.JSMC.2009.02.002

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/